EGFR and esophageal squamous cell carcinoma: These results revealed that Nimotuzumab only improved the radiosensitivity of ESCC cells with high expression of EGFR, suggesting a potential EGFR-dependent synergistic cytotoxicity of Nimotuzumab when combined with RT.